What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Cardiology
Robert A. Harrington mainly focuses on Internal medicine, Cardiology, Myocardial infarction, Acute coronary syndrome and Percutaneous coronary intervention.
His study in Surgery extends to Internal medicine with its themes.
His study in the field of Angina, Eptifibatide, ST segment and Electrocardiography also crosses realms of Task force.
His studies in Myocardial infarction integrate themes in fields like Coronary artery disease, Placebo and Stroke.
His Acute coronary syndrome study integrates concerns from other disciplines, such as Platelet aggregation inhibitor, Odds ratio, Observational study, Renal function and Severity of illness.
His research in Percutaneous coronary intervention intersects with topics in Anesthesia, Conventional PCI and Angioplasty.
His most cited work include:
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes (4782 citations)
- Universal definition of myocardial infarction. (2105 citations)
- Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial (1049 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Cardiology, Myocardial infarction, Percutaneous coronary intervention and Acute coronary syndrome.
His study connects Surgery and Internal medicine.
His work on Coronary artery disease, ST segment and ST elevation as part of general Cardiology study is frequently linked to In patient, bridging the gap between disciplines.
His Myocardial infarction study which covers Hazard ratio that intersects with Proportional hazards model.
His Percutaneous coronary intervention research integrates issues from Anesthesia, Conventional PCI and Angioplasty.
His work in the fields of Vorapaxar overlaps with other areas such as Alirocumab.
He most often published in these fields:
- Internal medicine (66.45%)
- Cardiology (52.00%)
- Myocardial infarction (38.94%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (66.45%)
- Cardiology (52.00%)
- Myocardial infarction (38.94%)
In recent papers he was focusing on the following fields of study:
Robert A. Harrington mainly investigates Internal medicine, Cardiology, Myocardial infarction, Acute coronary syndrome and Percutaneous coronary intervention.
His work on Stroke, Betrixaban and Cholesterol as part of general Internal medicine research is often related to Alirocumab and In patient, thus linking different fields of science.
His studies link Proportional hazards model with Cardiology.
His Myocardial infarction research is multidisciplinary, relying on both Aspirin and Hazard ratio.
His Acute coronary syndrome research focuses on subjects like Randomized controlled trial, which are linked to Intensive care medicine.
His Percutaneous coronary intervention study combines topics in areas such as Surgery, Clopidogrel, Conventional PCI and Platelet aggregation inhibitor.
Between 2016 and 2021, his most popular works were:
- Initial invasive or conservative strategy for stable coronary disease. (390 citations)
- What This Computer Needs Is a Physician: Humanism and Artificial Intelligence. (180 citations)
- Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery (137 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Surgery
His primary scientific interests are in Internal medicine, Cardiology, Myocardial infarction, Acute coronary syndrome and Randomized controlled trial.
Robert A. Harrington undertakes interdisciplinary study in the fields of Internal medicine and Alirocumab through his research.
Robert A. Harrington has researched Cardiology in several fields, including Stroke and Aspirin.
His study in the field of Unstable angina and Clopidogrel is also linked to topics like Oxygen supply.
Robert A. Harrington combines subjects such as Clinical research, Betrixaban, Quality of life, Intensive care medicine and Dosing with his study of Randomized controlled trial.
His work in Cangrelor addresses subjects such as Surgery, which are connected to disciplines such as Apixaban.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
